Roche stock drops 5% after report its Wegovy challenger is causing patients to vomit
Roche's obesity pill faces challenges with side effects that may impact its competitive edge in the weight-loss pharmaceutical market.
Five hundred new jobs coming in Chartres, south of Paris
Danish pharmaceutical giant Novo Nordisk is investing â¬2.1 billion in a French production site to expand the capacity and manufacturing of its anti-obesity drug.
Novo Nordisk's Semaglutide medication, originally meant for diabetes, is also effective against obesity and has massive global potential.
Goldman Sachs predicts that the global market for anti-obesity medication could reach $100 billion by 2030.